Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells

Cancer Cell

Volumn 3, Issue 4, 2003, Pages 377-386

  Sherman Baust, Cheryl A ^a   Weeraratna, Ashani T ^d   Rangel, Leticia B A ^a   Pizer, Ellen S ^b   Cho, Kathleen R ^c   Schwartz, Donald R ^c   Shock, Teresa ^a,e   Morin, Patrice J ^a,b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CISPLATIN; COLLAGEN TYPE 6; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL; CANCER GENETICS; CANCER GRADING; CELL CULTURE; CORRELATION ANALYSIS; EXTRACELLULAR MATRIX; GENE CONTROL; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; UNINDEXED SEQUENCE; UPREGULATION; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG RESISTANCE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMAN; OVARY TUMOR; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

SALVIA;

ANTINEOPLASTIC AGENTS; CISPLATIN; COLLAGEN TYPE VI; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0141484480     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00058-8     Document Type: Article

References (47)

1. Anderson K.M., Alrefai W.A., Anderson C.A., Ho Y., Jadko S., Ou D., Wu Y.B., Harris J.E. A response of Panc-1 cells to cis-platinum, assessed with a cDNA array. Anticancer Res. 22:2002;75-81.
2. Cohen S.M., Lippard S.J. Cisplatin. from DNA damage to cancer chemotherapy Prog. Nucleic Acid Res. Mol. Biol. 67:2001;93-130.
3. Dalton W.S. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist. Updat. 2:1999;285-288.
4. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR). role of integrins and resistance to apoptosis in human myeloma cell lines Blood. 93:1999;1658-1667.
5. DeClerck Y.A. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur. J. Cancer. 36:2000;1258-1268.
6. Deng H.B., Parekh H.K., Chow K.C., Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J. Biol. Chem. 277:2002;15035-15043.
7. Fan S., el-Deiry W.S., Bae I., Freeman J., Jondle D., Bhatia K., Fornace A.J. Jr., Magrath I., Kohn K.W., O'Connor P.M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54:1994;5824-5830.
8. Fink D., Aebi S., Howell S.B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 4:1998;1-6.
9. Gately D.P., Howell S.B. Cellular accumulation of the anticancer agent cisplatin. a review Br. J. Cancer. 67:1993;1171-1176.
10. Godwin A.K., Meister A., O'Dwyer P.J., Huang C.S., Hamilton T.C., Anderson M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA. 89:1992;3070-3074.
11. Hazlehurst L.A., Dalton W.S. Mechanisms associated with cell adhesion mediated drug resistance (CAM- DR) in hematopoietic malignancies. Cancer Metastasis Rev. 20:2001;43-50.
12. Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B., Cho K.R., Riggins G.J., Morin P.J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60:2000;6281-6287.
13. Hough C.D., Cho K.R., Zonderman A.B., Schwartz D.R., Morin P.J. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61:2001;3869-3876.
14. Ismail R.S., Baldwin R.L., Fang J., Browning D., Karlan B.Y., Gasson J.C., Chang D.D. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 60:2000;6744-6749.
15. Jones S.L., Hickson I.D., Harris A.L., Harnett P.R. Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma. Int. J. Cancer. 59:1994;388-393.
16. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 478:2001;23-43.
17. Kasahara K., Fujiwara Y., Nishio K., Ohmori T., Sugimoto Y., Komiya K., Matsuda T., Saijo N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 51:1991;3237-3242.
18. Lal A., Lash A.E., Altschul A.F., Velculescu V.E., Zhang L., McLendon R.E., Marra M.A., Prange C., Morin P.J., Papadopoulos N.et al. A public database for quantitative gene expression analysis in human cancers. Cancer Res. 59:1999;5403-5407.
19. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:2001;402-408.
20. Lohi J., Leivo I., Oivula J., Lehto V.P., Virtanen I. Extracellular matrix in renal cell carcinomas. Histol. Histopathol. 13:1998;785-796.
21. Lotem J., Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood. 80:1992;1750-1757.
22. Madden S.L., Galella E.A., Zhu J., Bertelsen A.H., Beaudry G.A. SAGE transcript profiles for p53-dependent growth regulation. Oncogene. 15:1997;1079-1085.
23. Makar A.P., Baekelandt M., Trope C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 56:1995;175-180.
24. Mamenta E.L., Poma E.E., Kaufmann W.K., Delmastro D.A., Grady H.L., Chaney S.G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 54:1994;3500-3505.
25. Mayer U., Poschl E., Nischt R., Specks U., Pan T.C., Chu M.L., Timpl R. Recombinant expression and properties of the Kunitz-type protease-inhibitor module from human type VI collagen alpha 3(VI) chain. Eur. J. Biochem. 225:1994;573-580.
26. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
27. Nishiyama A., Stallcup W.B. Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. Mol. Biol. Cell. 4:1993;1097-1108.
28. Omura G., Blessing J.A., Ehrlich C.E., Miller A., Yordan E., Creasman W.T., Homesley H.D. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study. Cancer. 57:1986;1725-1730.
29. Ozols R.F., Young R.C. Chemotherapy of ovarian cancer. Semin. Oncol. 11:1984;251-263.
30. Ozols R.F., Garvin A.J., Costa J., Simon R.M., Young R.C. Advanced ovarian cancer. correlation of histologic grade with response to therapy and survival Cancer. 45:1980;572-581.
31. Pfaff M., Aumailley M., Specks U., Knolle J., Zerwes H.G., Timpl R. Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. Exp. Cell Res. 206:1993;167-176.
32. Pinto A.L., Lippard S.J. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta. 780:1985;167-180.
33. Potapova O., Haghighi A., Bost F., Liu C., Birrer M.J., Gjerset R., Mercola D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272:1997;14041-14044.
34. Rangel L.B.A., Agarwal R., D'Souza T., Pizer E.S., Alò P.L., Schwartz D.R., Cho K.R., Morin P.J. Expression of tight junction proteins Claudin-3 and Claudin-4 in ovarian cancer. Clin. Cancer Res. in press:2003.
35. Rintoul R.C., Sethi T. The role of extracellular matrix in small-cell lung cancer. Lancet Oncol. 2:2001;437-442.
36. Ruhl M., Sahin E., Johannsen M., Somasundaram R., Manski D., Riecken E.O., Schuppan D. Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis via down-regulation of Bax. J. Biol. Chem. 274:1999;34361-34368.
37. Saha S., Sparks A.B., Rago C., Akmaev V., Wang C.J., Vogelstein B., Kinzler K.W., Velculescu V.E. Using the transcriptome to annotate the genome. Nat. Biotechnol. 20:2002;508-512.
38. Sakamoto M., Kondo A., Kawasaki K., Goto T., Sakamoto H., Miyake K., Koyamatsu Y., Akiya T., Iwabuchi H., Muroya T.et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum. Cell. 14:2001;305-315.
39. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., Chilvers E.R., Dransfield I., Donnelly S.C., Strieter R., Haslett C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis. a mechanism for small cell lung cancer growth and drug resistance in vivo Nat. Med. 5:1999;662-668.
40. Shimizu Y., Kamoi S., Amada S., Akiyama F., Silverberg S.G. Toward the development of a universal grading system for ovarian epithelial carcinoma. testing of a proposed system in a series of 461 patients with uniform treatment and follow-up Cancer. 82:1998;893-901.
41. St Croix B., Florenes V.A., Rak J.W., Flanagan M., Bhattacharya N., Slingerland J.M., Kerbel R.S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 2:1996;1204-1210.
42. Sutherland R.M., Durand R.E. Cell contact as a possible contribution to radiation resistance of some tumours. Br. J. Radiol. 45:1972;788-789.
43. Velculescu V.E., Zhang L., Vogelstein B., Kinzler K.W. Serial analysis of gene expression. Science. 270:1995;484-487.
44. Vogel W., Gish G.D., Alves F., Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol. Cell. 1:1997;13-23.
45. Wiberg C., Hedbom E., Khairullina A., Lamande S.R., Oldberg A., Timpl R., Morgelin M., Heinegard D. Biglycan and decorin bind close to the n-terminal region of the collagen VI triple helix. J. Biol. Chem. 276:2001;18947-18952.
46. Zembutsu H., Ohnishi Y., Tsunoda T., Furukawa Y., Katagiri T., Ueyama Y., Tamaoki N., Nomura T., Kitahara O., Yanagawa R.et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62:2002;518-527.
47. Zhang L., Zhou W., Velculescu V.E., Kern S.E., Hruban R.H., Hamilton S.R., Vogelstein B., Kinzler K.W. Gene expression profiles in normal and cancer cells. Science. 276:1997;1268-1272.